Silevertinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, brain penetrating, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, silevertinib selectively targets, irreversibly binds to, and inhibits the activity of various EGFR alterations and mutations, including certain intrinsic and acquired resistance mutations. This prevents EGFR-mediated signaling in susceptible tumor cells. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

**Synonyms:** - BDTX 1535 - BDTX-1535 - BDTX1535 - EGFR Inhibitor BDTX-1535 - EGFR Inhibitor Mutant-selective BDTX-1535 - EGFR Mutant Inhibitor BDTX-15356 - Mutant EGFR Inhibitor BDTX-1535 - Mutant-selective EGFR Inhibitor BDTX-1535 - SILEVERTINIB